AOD-9604 in Kisi — Fat Loss Peptide Research Guide
AOD-9604 research guide for Kisi. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Kisi trying to locate AOD-9604, the foundational reality is that this compound moves through online research channels. The practical takeaway for Kisi researchers: sourcing AOD-9604 comes down completely to vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. A legitimate AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide gives Kisi researchers the methodology to assess vendor quality rigorously and source research-grade AOD-9604 with confidence.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Kisi comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Before assessing any particular supplier, understand what genuine quality documentation contains — so you can tell whether a COA is complete and credible. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Red flags in AOD-9604 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that do not include endotoxin results. For Kisi researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Kisi
COA-verified · International tracking · Research grade
AOD-9604 operates beyond the scope of approved drug regulation — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Lyophilised AOD-9604 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. The main safety concern arising from sourcing in AOD-9604 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers combining AOD-9604 with other compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
